Clinical DevelopmentPelareorep's clinical momentum across multiple tumor types reinforces the view that Oncolytics is approaching a critical inflection point.
Earnings PotentialThe stock is believed to be undervalued at current levels with multiple catalysts ahead.
Regulatory ProgressPositive Phase 2 data in both settings, coupled with regulatory alignment, position pelareorep to advance to potential registration-enabling trials in 2025, supporting the view that Oncolytics is nearing a significant inflection point.